Antithrombotic therapy in TAVI
Manolis Vavuranakis
Konstantinos Kalogeras
Angelos Michail Kolokathis
Dimitrios Vrachatis
Nikolaos Magkoutis
Gerasimos Siasos
Euaggelos Oikonomou
Mafia Kariori
Theodoros Papaioannou
Maria Lavda
Carmen Moldovan
Ourania Katsarou
Dimitrios Tousoulis
摘要：Transcatheter aortic valve implantation (TAVI) carries a significant thromboembolic and concomitant bleeding risk,not only during the procedure but also during the periprocedural period.Many issues concerning optimal antithrombotic therapy after TAVI are still under debate.In the present review,we aimed to identify all relevant studies evaluating antithrombotic therapeutic strategies in relation to clinical outcomes after the procedure.Four randomized control trials (RCT) were identified analyzing the post-TAVI antithrombotic strategy with all of them utilizing aspirin lifelong plus clopidogrel for 3-6 months.Seventeen registries have been identified,with a wide variance among them regarding baseline characteristics,while concerning antiplatelet therapy,clopidogrel duration was ranging from 3-12 months.Four non-randomized trials were identified,comparing single vs.dual antiplatelet therapy after TAVI,in respect of investigating thromboembolic outcome events over bleeding complications.Finally,limited data from a single RCT and a retrospective study exist with regards to anticoagulant treatment during the procedure and the optimal antithrombotic therapy when concomitant atrial fibrillation.In conclusion,due to the high risk and frailty of the treated population,antithrombotic therapy after TAVI should be carefully evaluated.Diminishing ischaemic and bleeding complications remains the main challenge in these patients with further studies to be needed in this field.
机标关键词：
论文发表日期：2018-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：10( 66-75 )
英文信息